Top

Published in:

01-01-2008 | Adis Spotlight

Spotlight on Rasagiline in Parkinson’s Disease

Authors: Vicki Oldfield, Gillian M. Keating, Caroline M. Perry

Published in: CNS Drugs | Issue 1/2008

Abstract

Rasagiline (Azilect®) is a novel, selective, irreversible second-generation inhibitor of monoamine oxidase type B (MAO-B). It is administered orally once daily and is approved in the US, Canada, Mexico, Israel and the EU for use as monotherapy and as adjunct therapy in the treatment of Parkinson’s disease. Results of well designed clinical studies indicate that rasagiline is effective as initial monotherapy and improves Parkinson’s symptomatology in patients with early Parkinson’s disease. In addition, when administered in conjunction with levodopa, in patients with moderate to advanced disease and motor fluctuations, rasagiline reduces mean daily ‘off’ time and increases daily ‘on’ time without troublesome dyskinesias, compared with controls. Rasagiline is generally well tolerated as monotherapy and adjunctive therapy and is administered once daily. Thus, rasagiline, administered as a simple and convenient dosage regimen, is a well tolerated and effective option for monotherapy in patients with early Parkinson’s disease and for adjunctive therapy in patients with moderate to advanced disease.

The use of trade names is for product identification purposes only and does not imply endorsement.

Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-lR(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132(2): 500–6PubMedCrossRef

Speiser Z, Levy R, Cohen S. Effects of N-propargyl-l-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl 1998; 52: 287–300PubMedCrossRef

Lamensdorf I, Youdim MB, Finberg JP. Effect of long-term treatment with selective monoamine oxidase A and B nhibitors on dopamine release from rat striatum in vivo. J Neurochem 1996 Oct; 67(4): 1532–9PubMedCrossRef

Youdim MBH, Tipton KF. Rat striatal monoamine oxidase-B inhibition by 1-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson’s disease. Parkinsonism Rel Disord 2002; 8: 247–53CrossRef

Kupsch A, Sautter J, Gotz ME, et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm 2001; 108(8-9): 985–1009PubMedCrossRef

Finberg JPM, Wang J, Bankiewicz K, et al. Increased striatal dopamine production from L-DOPA following selective inhibition of monoamine oxidase B by R(+)-N-propargyl-l-aminoindan (rasagiline) in the monkey. J Neural Transm 1998; 52 Suppl.: 279–85CrossRef

Rabey JM, Sagi I, Huberman M, et al. Rasagiline mesylate, a new MAO-B inhibitorfor the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000; 23(6): 324–30PubMedCrossRef

Thebault JJ, Guillaume M, Levy R. Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy 2004 Oct; 24(10): 1295–305PubMedCrossRef

Finberg JP, Youdim MB. Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat. Br J Pharmacol 1985 Jun; 85(2): 541–6PubMedCrossRef

10.

Finberg JP, Youdim MB. Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours. Neuropharmacology 2002 Dec; 43(7): 1110–8PubMedCrossRef

11.

Eliash S, Shteter N, Eilam R. Neuroprotective effect of rasagiline, a monoamine oxidase-B inhibitor, on spontaneous cell degeneration in a rat model. J Neural Transm 2005 Mar 15; 112(991–1003)

12.

Waibel S, Reuter A, Malessa S, et al. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 2004 Sep; 251(9): 1080–4PubMedCrossRef

13.

Blandini F, Armentero MT, Fancellu R, et al. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp Neurol 2004 Jun; 187(2): 455–9PubMedCrossRef

14.

Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neuro Sci 2006 Apr; 7(4): 295–309CrossRef

15.

Speiser Z, Mayk A, Eliash S, et al. Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat. J Neural Transm 1999; 106(7–8): 593–606PubMedCrossRef

16.

Huang W, Chen Y, Shohami E, et al. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol 1999 Feb 5; 366(2-3): 127–35PubMedCrossRef

17.

Finberg JP, Takeshima T, Johnston JM, et al. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 1998 Mar 9; 9(4): 703–7PubMedCrossRef

18.

Goggi J, Theofilopoulos S, Riaz SS, et al. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture. Neuroreport 2000 Dec 18; 11(18): 3937–41PubMedCrossRef

19.

Finberg JP, Lamensdorf I, Weinstock M, et al. Pharmacology of rasagiline (N-propargyl-1R-aminoindan). Adv Neurol 1999; 80: 495–9PubMed

20.

Maruyama W, Youdim MB, Naoi M. Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann N Y Acad Sci 2001 Jun; 939: 320–9PubMedCrossRef

21.

Naoi M, Maruyama W, Youdim MB, et al. Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 2003; 11(2): 175–81PubMedCrossRef

22.

Abu-Raya S, Tabakman R, Blaugrund E, et al. Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol 2002 Jan 11; 434(3): 109–16PubMedCrossRef

23.

Abu-Raya S, Blaugrund E, Trembovler V, et al. Rasagiline, a monoamine oxidase-B inhibitor, protects NGF-differentiated PC12 cells against oxygen-glucose deprivation. J Neurosci Res 1999 Nov 1; 58(3): 456–63PubMedCrossRef

24.

Weinreb O, Bar-Am O, Amit T, et al. Neuroprotection via prosurvival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004 Sep 18; 12: 1471–3

25.

Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drags rasagiline and selegiline. Neurosci Lett 2004 Jan 30; 355(3): 169–72PubMedCrossRef

26.

Youdim MB, Wadia A, Tatton W, et al. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 2001 Jun; 939: 450–8PubMedCrossRef

27.

Bar Am O, Amit T, Youdim M. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004 Jan 30; 355(3): 169–72PubMedCrossRef

28.

Maruyama W, Akao Y, Youdim M, et al. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin N-methyl(R)salsolinol. J Neurochem 2001; 78: 727–35PubMedCrossRef

29.

Maruyama W, Takahashi T, Youdim M, et al. The anti-Parkinson drag, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 2002 Apr; 109(4): 467–81PubMedCrossRef

30.

Akao Y, Maruyama W, Shimizu S, et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)-salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 2002; 82: 913–23PubMedCrossRef

31.

Data on file, Teva Pharmaceutical Industries, 2007 Jun

32.

Eliash S, Speiser Z, Cohen S. Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats. J Neural Trans 2001; 108(8-9): 909–23CrossRef

33.

Bonneh-Barkay D, Ziv N, Finberg JP. Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells. Neuropharmacology 2005 Mar; 48(3): 406–16PubMedCrossRef

34.

Maruyama W, Naoi M. Neuroprotection by deprenyl and related compounds. Mech Ageing Dev 1999 Nov; 111(2-3): 189–200PubMedCrossRef

35.

Carrillo MC, Minami C, Kitani K, et al. Enhancing effect of rasagiline on Superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000 Jun 23; 67(5): 577–85PubMedCrossRef

36.

Maruyama W, Akao Y, Youdim MB, et al. Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-l(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm Suppl 2000; 60 Suppl.: 171–86

37.

Bar-Am O, Yogev-Falach M, Amit T, et al. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004 Jun; 89(5): 1119–25PubMedCrossRef

38.

Abassi ZA, Binah O, Youdim MB. Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline. Br J Pharmacol 2004 Oct; 143(3): 371–8PubMedCrossRef

39.

Teva Pharma GmbH. Rasagiline (Azilect®): summary of product characteristics [online]. Available from URL: http://www.emc.medicines.org.uk/emc/assets/c/html/DisplayDoc.asp?DocumentID=16273 [Accessed 2007 Jul 17]

40.

Teva Neuroscience Inc. Azilect® (rasagiline) prescribing information [online]. Available from URL: http://www.azilect.com/ContentRoot/Prescribing_Information [Accessed 2007 June 21]

41.

Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002 Dec; 59(12): 1937–43CrossRef

42.

Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005 Mar 12; 365: 947–54PubMedCrossRef

43.

Parkinson Study Group. A randomised placebo-controlled trial with rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. Arch Neurol 2005; 62: 241–8CrossRef

44.

Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561–6CrossRef

45.

Lew MF, Hauser RA, Hurtig HI, et al. Long-term efficacy of rasagiline in Parkinson’s disease [abstract]. Neurology 2005; 64Suppl. 1: A396. Plus poster presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders; 2005 Mar 5–8; New Orleans (LA)

46.

Hauser RA, Lew MF, Hurtig HI, et al. Early treatment with rasagiline is more beneficial than delayed treatment start in the long-term management of Parkinson’s disease: analysis of the TEMPO ITT cohort [abstract no. 10 plus poster]. 16th International Congress on Parkinson’s Disease and Related Disorders; 2005 June 5–9; Berlin

47.

Stern M, White W, de Marcaida J, et al. Rasagiline does not affect blood pressure in Parkinsons’s disease patients following meals unrestricted in tyramine content. Mov Disord 2006 2006; 21Suppl. 15: S487

48.

Blindauer K, for the Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson’s disease (the TEMPO Study) [abstract no. P05.077]. Neurology 2001; 56Suppl. 3: 345

49.

deMarcaida JA, Schwid SR, White WB, et al. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006; 21(10): 1716–21PubMedCrossRef

50.

de Marcaida JA. Rasagiline does not promote tyramine pressor responses [abstract no. P451]. Mov Disord 2005; 20 Suppl. 10: S133. Plus poster presented at the 9th International Congress of Parkinson’s Disease and Movement Disorders; 2005 Mar 5–8; New Orleans (LA)

51.

Guillaume M, Thebault J, Cohen S. Assessment of the potential for pharmacodynamic interaction between rasagiline and oral tyramine in healthy subjects [poster no. P963]. 10th International Congress of the Movement Disorder Society; 2006 Oct 28–Nov 2; Kyoto

Title: Spotlight on Rasagiline in Parkinson’s Disease
Authors: Vicki Oldfield
Gillian M. Keating
Caroline M. Perry
Publication date: 01-01-2008
Publisher: Springer International Publishing
Published in: CNS Drugs / Issue 1/2008
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200822010-00007

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Spotlight on Rasagiline in Parkinson’s Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2008

National Use of Thrombolysis with Alteplase for Acute Ischaemic Stroke via Telemedicine in Denmark

Quetiapine

Neurobiological and Clinical Effects of the Antidepressant Tianeptine

The Role of Peroxisome Proliferator-Activated Receptor-γ PPARγ) in Alzheimer’s Disease

Quetiapine

Antiepileptic Drugs in Non-Epilepsy Disorders